Hormones HR Nurses 
The Pharma Data
MARCH 25, 2021
months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53 This real-world cohort includes more than 1,400 women with HR+, HER2- mBC with any extent of visceral disease. months with IBRANCE plus letrozole versus 11.9 to 0.82; P=0.0002). in the IBRANCE group and 68.0%
Pfizer
AUGUST 15, 2022
PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which PAXLOVID belongs (i.e., PAXLOVID is not authorized for use for longer than 5 consecutive days.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer
DECEMBER 13, 2022
PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir.
Pfizer
JANUARY 27, 2023
A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Limited published data reports that ritonavir is present in human milk.
Pfizer
DECEMBER 20, 2022
PAXLOVID may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir.
Pfizer
JANUARY 27, 2023
telehealth, in-person visit) with a physician, advanced practice registered nurse, or physician assistant licensed or authorized under state law to prescribe drugs, if any of the following apply: Sufficient information is not available to assess renal and hepatic function.
The Pharma Data
JUNE 18, 2021
The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. Isolated growth hormone deficiency. ?
Expert insights. Personalized for you.
52 
Let's personalize your content